PRESTIGE CONSUMER HEALTHCARE (PBH)
US74112D1019 - Common Stock
Taking everything into account, PBH scores 5 out of 10 in our fundamental rating. PBH was compared to 198 industry peers in the Pharmaceuticals industry. PBH has an average financial health and profitability rating. PBH has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year PBH has reported negative net income.
In the past year PBH had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PBH reported negative net income in multiple years.
In the past 5 years PBH always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of PBH (-2.42%) is better than 79.49% of its industry peers.
The Return On Equity of PBH (-5.04%) is better than 82.05% of its industry peers.
With an excellent Return On Invested Capital value of 8.51%, PBH belongs to the best of the industry, outperforming 88.72% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PBH is significantly below the industry average of 16.38%.
The 3 year average ROIC (7.67%) for PBH is below the current ROIC(8.51%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.42% | ||
| ROE | -5.04% | ||
| ROIC | 8.51% |
ROA(3y)2.65%
ROA(5y)2.19%
ROE(3y)6.49%
ROE(5y)5.67%
ROIC(3y)7.67%
ROIC(5y)7.42%
1.3 Margins
PBH has a better Operating Margin (30.81%) than 95.38% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
Looking at the Gross Margin, with a value of 55.23%, PBH is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.81% | ||
| PM (TTM) | N/A | ||
| GM | 55.23% |
OM growth 3Y0.11%
OM growth 5Y0.25%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PBH is creating some value.
The number of shares outstanding for PBH has been reduced compared to 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, PBH has an improved debt to assets ratio.
2.2 Solvency
PBH has an Altman-Z score of 2.54. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.54, PBH is doing good in the industry, outperforming 72.31% of the companies in the same industry.
PBH has a debt to FCF ratio of 5.18. This is a neutral value as PBH would need 5.18 years to pay back of all of its debts.
PBH's Debt to FCF ratio of 5.18 is amongst the best of the industry. PBH outperforms 84.62% of its industry peers.
PBH has a Debt/Equity ratio of 0.75. This is a neutral value indicating PBH is somewhat dependend on debt financing.
PBH's Debt to Equity ratio of 0.75 is on the low side compared to the rest of the industry. PBH is outperformed by 68.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | 5.18 | ||
| Altman-Z | 2.54 |
ROIC/WACC1.05
WACC8.07%
2.3 Liquidity
PBH has a Current Ratio of 3.09. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
PBH has a Current ratio of 3.09. This is comparable to the rest of the industry: PBH outperforms 47.69% of its industry peers.
PBH has a Quick Ratio of 1.92. This is a normal value and indicates that PBH is financially healthy and should not expect problems in meeting its short term obligations.
PBH has a worse Quick ratio (1.92) than 61.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.09 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
PBH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -140.39%.
The Revenue has been growing slightly by 2.29% in the past year.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 1.61% on average per year.
EPS 1Y (TTM)-140.39%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q1.92%
Revenue 1Y (TTM)2.29%
Revenue growth 3Y5.4%
Revenue growth 5Y1.61%
Revenue growth Q2Q2.62%
3.2 Future
The Earnings Per Share is expected to grow by 37.97% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 2.05% on average over the next years.
EPS Next Y360.43%
EPS Next 2Y118.67%
EPS Next 3Y70.07%
EPS Next 5Y37.97%
Revenue Next Year1.33%
Revenue Next 2Y1.79%
Revenue Next 3Y2.02%
Revenue Next 5Y2.05%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PBH. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 14.98, PBH is valued correctly.
Based on the Price/Forward Earnings ratio, PBH is valued cheaper than 85.13% of the companies in the same industry.
PBH's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 14.98 |
4.2 Price Multiples
PBH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBH is cheaper than 81.54% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 87.69% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.98 | ||
| EV/EBITDA | 12.3 |
4.3 Compensation for Growth
PBH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PBH's earnings are expected to grow with 70.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y118.67%
EPS Next 3Y70.07%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRESTIGE CONSUMER HEALTHCARE
NYSE:PBH (5/3/2024, 7:11:11 PM)
After market: 69.96 -0.04 (-0.06%)70
-1.26 (-1.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.48B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 14.98 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.42% | ||
| ROE | -5.04% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 30.81% | ||
| PM (TTM) | N/A | ||
| GM | 55.23% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.09 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-140.39%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y360.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2.29%
Revenue growth 3Y5.4%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y